Clinical trial
Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache
NCT00471952 · Diamond Headache Clinic, Other · Completed
Key facts
| NCT number | NCT00471952 |
|---|---|
| Title | Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache |
| Official title | Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache |
| Lead sponsor | Diamond Headache Clinic, Other |
| Collaborators | Merck Sharp & Dohme LLC Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Migraine With Aura, Migraine Without Aura |
| Intervention type | Drug |
| Interventions | Maxalt 10mg MLT plus Caffeine 75mg, Maxalt 10mg MLT plus Placebo, Placebo + Placebo |
| Enrollment | 50 |
| Start date | Apr 1, 2007 |
| Primary completion | Feb 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | May 10, 2007 |
| Last update posted | Apr 25, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: